The Latest Cardiac and Vascular News
Portage, Michigan, Feb. 19, 2025 (GLOBE NEWSWIRE) — Stryker (NYSE: SYK), a global leader in medical technologies, announced today that it has completed the acquisition of Inari Medical, Inc. (NASDAQ: NARI), a company that provides innovative solutions for venous thromboembolism (VTE) clot removal without the use of thrombolytic drugs. The addition of Inari brings an established peripheral vascular position to Stryker in the fast-growing VTE segment.
Portage, Michigan and Irvine, California, Jan. 06, 2025 (GLOBE NEWSWIRE) — Stryker (NYSE: SYK), a global leader in medical technologies, announced today a definitive agreement to acquire all of the issued and outstanding shares of common stock of Inari Medical, Inc. (NASDAQ: NARI) for $80 per share in cash, representing a total fully diluted equity value of approximately $4.9 billion. Inari, which was founded in 2011, will bring a leading peripheral vascular position in the fast-growing segment of venous thromboembolism (VTE) to Stryker. Inari’s innovative product portfolio is highly complementary to Stryker’s Neurovascular business and includes mechanical thrombectomy solutions for peripheral vascular diseases such as deep vein thrombosis and pulmonary embolism.
PORTAGE, Mich., USA, Sept. 20, 2024 /PRNewswire/ — Stryker (NYSE: SYK), a global leader in medical technologies, announced today that it has completed the acquisition of NICO Corporation, a privately held company providing a systematic approach to minimally invasive surgery for tumor and…
Portage, Michigan, Jan. 30, 2024 (GLOBE NEWSWIRE) — Stryker (NYSE:SYK) reported operating results for the fourth quarter and full year of 2023: Fourth Quarter Results Reported net sales increased 11.8% to $5.8 billion Organic net sales increased 11.4% Reported operating income margin of 21.6% Adjusted operating income margin(1) increased 60 […]
Kalamazoo, Michigan, Nov. 02, 2023 (GLOBE NEWSWIRE) — Stryker (NYSE:SYK) reported operating results for the third quarter of 2023: Third Quarter Results Reported net sales increased 9.6% to $4.9 billion Organic net sales increased 9.2% Reported operating income margin of 19.0% Adjusted operating income margin(1) increased 110 bps to 23.4% […]
KALAMAZOO, Michigan, USA, May 2, 2023 /PRNewswire/ — Stryker (NYSE:SYK), one of the world’s leading medical technology companies, announced today that it has completed the acquisition of Cerus Endovascular Ltd., a privately held, commercial-stage, medical device company engaged in the design and development of neurointerventional devices for the treatment of intracranial aneurysms. […]
HINGHAM, Mass., Dec. 27, 2021 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT) announced that it has entered into a strategic collaboration agreement with Stryker, a leading global medical technology company. The company will collaborate with Stryker’s Neurovascular division to integrate its neurovascular instruments with Microbot’s LIBERTY Robotic System to […]
KALAMAZOO, Michigan, USA, Aug. 3, 2020 /PRNewswire/ — Stryker announced today that it has received U.S. Food and Drug Administration (FDA) approval for an expanded indication of its Neuroform Atlas Stent System, becoming the first and only adjunctive stent approved for use in the posterior (back of the brain) circulation. Aneurysms in the posterior […]
KALAMAZOO, Michigan, USA, Dec. 27, 2019 /PRNewswire/ — Stryker announced today that the company is launching a voluntary field action on specific units of the LIFEPAK 15 monitor/defibrillators. The company is notifying a population of LIFEPAK 15 customers of an issue that may cause their devices to fail to deliver a defibrillation […]
REDMOND, Wash., USA, April 11, 2019 /PRNewswire/ — Stryker has launched the company’s newest defibrillation solution, the LIFEPAK® CR2 defibrillator with LIFELINKcentral™ AED program manager, in the United States. The company has announced that the LIFEPAK CR2 automated external defibrillator (AED) has received Premarket Approval (PMA) by FDA. The LIFPAK CR2 AED was previously released […]
